Last updated on October 2018

A clinical trial sponsored by Aimmune Therapeutics, Inc. for a research study for the treatment of peanut allergy

Brief description of study

This is a multicenter, randomized, double-blind, placebo-controlled safety study of AR101 using the characterized oral desensitization immunotherapy (CODIT ) regimen in peanut-allergic children.

Detailed Study Description

The primary objective is to assess the safety and tolerability of AR101 when used in a CODIT regimen for approximately 6 months in peanut-allergic children.

Clinical Study Identifier: NCT03126227

Contact Investigators or Research Sites near you

Start Over

Sher Allergy Specialists - Center for Cough
Largo, FL United States